As­traZeneca jet­ti­sons an­oth­er drug, this time grab­bing $30M for out-li­cens­ing deal

Add one more drug to As­traZeneca’s grow­ing pile of pipeline drugs it’s jet­ti­son­ing. This time, the deal fo­cus­es on an ear­ly-stage res­pi­ra­to­ry drug dubbed AZD7986.

Bridge­wa­ter, NJ-based In­smed $IN­SM grabbed the oral DPP1 drug for $30 mil­lion up­front and an­oth­er $120 mil­lion in a grab-bag of de­vel­op­ment and sales mile­stones. In­smed re­cent­ly com­plet­ed a $55 mil­lion debt fi­nanc­ing deal and plans to add an­oth­er $30 mil­lion to pay for the ac­qui­si­tion from As­traZeneca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.